Entity

Time filter

Source Type

Petaling Jaya, Malaysia

Subramani B.,Nichi Asia Life science Sdn. Bhd | Ratnavelu K.,Nilai Cancer Institute NCI Hospital | Pullai C.R.,Nichi Asia Life science Sdn. Bhd | Krishnan K.,Nichi Asia Life science Sdn. Bhd | And 3 more authors.
Oncology Letters | Year: 2013

Current modalities of cancer treatment, including surgery, chemotherapy and radiotherapy, show marginal therapeutic responses in cancer patients. In adoptive immunotherapy, interleukin-2 (IL-2) activated immune cells demonstrated notable results in patients with advanced malignant disease. The present study reports the efficacy and safety of repetitive infusions of autologous immune enhancement therapy (AIET) in a stage IV colonic cancer patient who had already received first-line chemotherapeutic drugs. Peripheral blood was aspirated from the patient. Specifically, natural killer (NK) cells and T-lymphocytes were isolated from the peripheral blood mononuclear cells (PBMCs). These cells were activated and expanded ex vivo for 14 days and were transfused intravenously to the patient. After six infusions of AIET, the carcinoembryonic antigen (CEA) level was decreased from 901 to 437 U/ml, regression of lesions was noted and there were no adverse reactions during the course of this therapy. Thus, AIET may be a promising anticancer approach to eradicate tumor cells with other conventional therapies. Source


Ratnavelu K.,Nilai Cancer Institute NCI Hospital | Subramani B.,Nichi Asia Life science Sdn. Bhd | Subramani B.,Acharya Nagarjuna University | Pullai C.R.,Nichi Asia Life science Sdn. Bhd | And 10 more authors.
Oncology Letters | Year: 2013

Rare types of cancer are often not effectively treated by approaches such as chemotherapy and radiotherapy, although their side-effects persist. Immunotherapy has been gaining attention worldwide with growing examples of its anticancer activity demonstrated in vivo. This case report describes a 35-year-old male who suffered from advanced epithelioid sarcoma and underwent 18 cycles of chemotherapy without any significant response, who suffered adverse effects that caused lung collapse. A notable response was observed following the administration of autologous immune enhancement therapy (AIET), which involves a process of isolation, activation and expansion of natural killer (NK) and T cells, which were obtained from the patient's own (autologous) peripheral blood. With the present data and the response of the patient to AIET, it may be proposed that AIET is beneficial for patients suffering from advanced epithelioid sarcoma without producing adverse effects. Source

Discover hidden collaborations